AIM
VRDN icon

Aigen Investment Management’s Viridian Therapeutics VRDN Stock Holding History

Aigen Investment Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,217
Closed -$411K – 802
2025
Q4 		$411K Buy
+13,217
New +$363K 0.1% 279
2023
Q3 		– Sell
-9,419
Closed -$224K – 1101
2023
Q2 		$224K Buy
+9,419
New +$242K 0.03% 585

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Aigen Investment Management's VRDN Position: Q1 2026 in Review

Aigen Investment Management sold out of Viridian Therapeutics (VRDN) in Q1 2026, closing a stake of 13,217 shares — an estimated $411K sold.

Aigen Investment Management first reported a position in VRDN in Q2 2023 and held it in 2 quarters. The position peaked at $411K in Q4 2025. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • Aigen Investment Management reported no remaining Viridian Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Aigen Investment Management sold 13,217 Viridian Therapeutics shares in Q1 2026, an estimated $411K.
  • Aigen Investment Management first reported a position in Viridian Therapeutics in Q2 2023 and held it in 2 quarters.
  • Aigen Investment Management's Viridian Therapeutics position peaked at $411K in Q4 2025.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Aigen Investment Management's 13F filing for Q1 2026, filed 15 May 2026.